| Literature DB >> 31048881 |
Lara Vojnov1, Miriam Taegtmeyer2, Caroline Boeke1, Jessica Markby1, Lindsay Harris1, Meg Doherty3, Trevor Peter1, Nathan Ford3.
Abstract
BACKGROUND: In most high HIV burden countries, many HIV patients do not have reliable access to required diagnostic laboratory tests. Task shifting of clinical tasks to lower cadres of health care workers and lay counselors has been successful in scaling up treatment for HIV and may also be an effective strategy in expanding access to essential diagnostic testing.Entities:
Mesh:
Year: 2019 PMID: 31048881 PMCID: PMC6497381 DOI: 10.1371/journal.pone.0216277
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA flow chart.
Study characteristics of included studies in meta-analysis.
| Author | Ref # | Journal | Year | Countries of study | Type of study | Years of study | Site type | Test | Technology | Sample type | Comparator |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Agizew | [ | PLoS One | 2017 | Botswana | step-wedged clinical trial | 2012–2014 | HIV C&T sites | POC TB/RIF | Xpert MTB/RIF | Sputum | Xpert MTB/RIF |
| Arnett | [ | IAS poster | 2013 | Tanzania | technical evaluation | unknown | clinics | POC CD4 | Alere Pima | unknown | Pima in lab |
| finger-prick capillary | laboratory CD4 | ||||||||||
| finger-prick capillary microtube | laboratory CD4 | ||||||||||
| venous | laboratory CD4 | ||||||||||
| Benzaken | [ | STI | 2014 | Brazil | prospective observational | 2010–2011 | remote clinics | syphilis | TR Syphilis 3.0-SD Bioline | DTS (6 each) | known results |
| Bile | [ | CROI poster | 2017 | Bostwana | randomised controlled trial | 2013–2016 | mobile and home testing | POC CD4 | Alere Pima | unknown | laboratory Alere Pima |
| Brouillette | [ | IAS poster | 2013 | Uganda | retrospective observational | 2011–2012 | clinics | POC CD4 | Alere Pima | ||
| Bwana | [ | PLoS One | 2015 | Kenya | prospective observational | 2014–2015 | rural clinics, sub-district hospital | POC CD4 | BD FACS Presto | finger-prick capillary | BD FACS Presto |
| BD FACS Count | |||||||||||
| BD FACS Calibur | |||||||||||
| Alere Pima | |||||||||||
| Daneau | [ | PLoS One | 2016 | Tanzania | prospective observational | 2014 | urban clinics | POC CD4 | BD FACS Presto | finger-prick capillary | BD FACSCalibur |
| venous blood | |||||||||||
| Diaw | [ | JAIDS | 2011 | Senegal | technical evaluation | 2009–2010 | urban clinics | POC CD4 | Alere Pima | finger-prick capillary | BD FACSCount |
| Fajardo | [ | Bulletin WHO | 2015 | 9 sSA | retrospective observational | 2011–2013 | primary and mobile clinics, community | POC CD4 | Alere Pima | NA | |
| Garone | [ | AIDS conf | 2014 | Malawi | prospective observational | 2013–2014 | primary clinic | viral load | dried blood spot | finger-prick capillary | NA |
| Gimbel-Sherr | [ | HRH | 2007 | Mozambique | retrospective operational | 2004–2005 | urban clinics | POC CD4 | not indicated | unknown | |
| Glencross | [ | JIAS | 2012 | South Africa | technical evaluation | unknown | urban hospital | POC CD4 | Alere Pima | finger-prick capillary | Beckman Coulter PLG |
| urban clinic | |||||||||||
| Gous | [ | PLoS One | 2013 | South Africa | technical evaluation | 2012 | urban hospital | POC CD4 | Alere Pima | finger-prick capillary | Beckman Coulter PLG |
| Hemoglobin | HemoCue Hb201+ | Advia 120, 2120 | |||||||||
| ALT | Roche Reflotron Plus | Synchron DXC 800 | |||||||||
| Cr | Roche Reflotron Plus | Synchron DXC 800 | |||||||||
| Gous | [ | JAIDS | 2016 | South Africa | prospective observational | 2010–2012 | urban clinics | POC CD4 | Alere Pima | venous blood / venidrop | Beckman Coulter |
| Hemoglobin | HemoCue Hb201+ | Advia 120 and 2120 | |||||||||
| ALT | Roche Reflotron Plus | Advia 1800 and Synchron DXC 801 | |||||||||
| Creatinine | Roche Reflotron Plus | Advia 1800 and Synchron DXC 804 | |||||||||
| Lactate | Accutrend | Advia 1800 | |||||||||
| Jani | [ | AIDS | 2011 | Mozambique | technical evaluation | 2009–2010 | urban clinics | POC CD4 | Alere Pima | finger-prick capillary | BD FACSCalibur |
| POC CD4 | Alere Pima | Alere Pima in lab | |||||||||
| ALT | Roche Reflotron Plus | Selectra Junior | |||||||||
| AST | Roche Reflotron Plus | Selectra Junior | |||||||||
| Hemoglobin | HemoCue Hb201+ | Sysmex SF3000 | |||||||||
| Jani | [ | AIDS | 2016 | Mozambique | retrospective observational | 2012–2013 | clinics | POC CD4 | Alere Pima | finger-prick capillary | NA |
| Kaindjee-Tjituka | [ | Afr J Lab Med | 2017 | Namibia | prospective observational | 2011 | public clinics | POC CD4 | Alere Pima | finger-prick capillary | NA |
| Kohatsu | [ | PLoS One | 2018 | Tanzania | prospective observational | 2011 | urban clinics | POC CD4 | Alere Pima | finger-prick capillary direct drop | BD FACSCalibur |
| finger-prick capillary microtube | |||||||||||
| venous blood | |||||||||||
| Lassovski | [ | poster | 2013 | Swaziland | retrospective observational | 2010–2012 | rural/urban clinics | POC CD4 | Alere Pima | controls | NA |
| creatinine | Roche Reflotron Plus | ||||||||||
| glucose | Roche Reflotron Plus | ||||||||||
| potassium | Roche Reflotron Plus | ||||||||||
| ALAT | Roche Reflotron Plus | ||||||||||
| Liang | [ | Chin Med J | 2015 | China | prospective observational | 2012 | urban clinics | POC CD4 | Alere Pima | finger-prick capillary | BD FACSCalibur |
| venous blood | |||||||||||
| MacLennan | [ | AIDS | 2007 | Malawi | technical evaluation | 2006 | urban clinic | POC CD4 | BD FACSCalibur | finger-prick capillary | venous FACSCalibur |
| Maiers | [ | 2014 | South Africa | prospective observational | urban clinic | blood collection of 150ul | finger-prick capillary | ||||
| Manabe | [ | PLoS One | 2012 | Uganda | technical evaluation | 2009 | urban hospital | POC CD4 | Alere Pima | finger-prick capillary | |
| Morawski | [ | JAIDS | 2013 | Uganda | technical evaluation | urban clinics | POC CD4 | Alere Pima | venous blood | BD FACSCalibur | |
| Mwanja | [ | IAS poster | 2013 | Tanzania | retrospective observational | 2011–2012 | clinics | POC CD4 | Alere Pima | finger-prick capillary | |
| Mwau | [ | PLoS One | 2014 | Kenya | technical evaluation | 2014 | rural clinics | POC CD4 | Zyomyx MyT4 | finger-prick capillary | BD FACSCount |
| Zyomyx in lab | |||||||||||
| Myer | [ | JIAS | 2013 | South Africa | technical evaluation | unknown | urban clinic | POC CD4 | Alere Pima | venous blood | laboratory assay |
| Negedu-Momoh | [ | PLoS One | 2017 | Nigeria | prospective observational | 2015–2016 | rural hospital clinic | POC CD4 | BD FACSPresto | finger-prick capillary | BD FACSCalibur |
| Olugbenga | [ | PLoS One | 2018 | Nigeria | prospective observational | antenatal clinics | HIV/Syphilis | SD BIOLINE HIV/Syphilis | finger-prick capillary | SD BIOLINE HIV/Syphilis in lab | |
| TPHA Lab | |||||||||||
| Pinto | [ | PLoS One | 2015 | Brazil | prospective observational | 2013–2014 | rural clinics | POC CD4 | Alere Pima | finger-prick capillary | BD FACSCalibur |
| venous blood | |||||||||||
| Pollock | [ | PLoS One | 2013 | Vietnam | urban clinic | ALT | Diagnostics for All | finger-prick capillary | Roche Cobas ALT | ||
| Riberio | [ | STI | 2014 | Brazil | prospective observational | 2011–2012 | urban outreach | syphilis | SD Bioline Syphilis 3.0 | DTS (4 each) | known results |
| Rutstein | [ | JCV | 2014 | Malawi | technical evaluation | unknown | remote hospitals | viral load | dried blood spot | finger-prick capillary | NA |
| Sangala | [ | IJTLD | 2006 | Malawi | qualitative | unknown | rural clinics, district hospital | tuberculosis | sputum collection | sputum | NA |
| Scott | [ | BMC | 2015 | global | pooled data meta-analysis | 2009–2014 | various | CD4 | Alere Pima | finger-prick capillary | conventional CD4 |
| Simmonds | [ | IAS poster | 2018 | Zimbabwe | retrospective observational | 2016–2017 | POC EID | Alere q HIV 1/2 Detect | heel-prick capllary | NA | |
| Tsibolane | [ | unpublished | 2014 | South Africa | retrospective observational | 2014 | urban/rural clinics | POC CD4 | Alere Pima | finger-prick capillary | NA |
| Wake | [ | JAIDS | 2018 | South Africa | prospective observational | 2016–2018 | HIV clinics | POC CrAg | CrAg LFA | finger-prick capillary | POC CrAG |
| Williams | [ | Clin Infect Dis | 2015 | Uganda | prospective observational | 2013–2014 | POC CrAg | CrAg LFA | finger-prick capillary | POC CrAG | |
| Zeh | [ | J Immunol Methods | 2017 | Kenya | prospective observational | unknown | rural hospital clinic | POC CD4 | Alere Pima | finger-prick capillary | BD FACSCalibur |
| venous blood | BD FACSCalibur | ||||||||||
| finger-prick capillary | Alere Pima in lab | ||||||||||
| Zinyowera | [ | unpublished | Zimbabwe | prospective observational | unknown | central | POC viral load | SAMBA II | proficiency panel | known results | |
| Zinyowera | [ | JAIDS | 2010 | Zimbabwe | technical evaluation | unknown | urban clinic | POC CD4 | Alere Pima | finger-prick capillary | BD FACSCalibur |
C&T: care and treatment
ALT: alanine aminotransferase
AST: aspartate aminotransferase
DTS: dried tube specimens
Known results: proficiency panels with already known results
Test types, technologies used, and non-laboratory health care cadres in included studies.
| CD4: Alere Pima (device), Zyomyx MyT4 (device), BD FACSPresto (device) | Nurses (25 studies): staff, technicians, assistants, practitioners |
| Syphilis: SD Bioline (lateral flow) | Physicians (2) |
| HIV nucleic acid: dried blood spot (specimen), SAMBA II (device), Alere q HIV 1/2 Detect (device) | Health surveillance assistants (2) |
| ALT: Roche Reflotron Plus (device), Diagnostics for All (lateral flow) | ANC provider (2) |
| AST: Roche Reflotron Plus (device) | Clinic staff (7) |
| Hemoglobin: HemoCue Hb201+ (device) | Laypersons (1) |
| Creatinine, glucose, potassium: Roche Reflotron Plus (device) | Lay counsellors (6) |
| Tuberculosis: sputum collection (specimen), Cepheid GeneXpert MTB/Rif (device) | Biologists (2) |
| Cryptococcal antigen: IMMY CrAg LFA (lateral flow) | Microscopists (2) |
| Lactate: Accutrend (device) | VCT staff (1) |
| Phlebotomist (1) |
Fig 2Forest plots of point-of-care CD4 diagnostic accuracy performance by non-laboratory staff.
(a) point-of-care CD4 testing by non-laboratory staff compared to conventional laboratory-based testing by professional laboratory staff; (b) point-of-care CD4 testing by non-laboratory staff compared to point-of-care CD4 testing by professional laboratory staff; the shaded box represents +/- 50 cells/ul in (a) and (b). (c) sensitivity of correctly classifying patients below a CD4 threshold of 350 cells/ul; (d) specificity of correctly classifying patients above a CD4 threshold of 350 cells/ul.
Fig 3Forest plots of point-of-care ALT and hemoglobin diagnostic accuracy performance by non-laboratory staff.
(a) point-of-care ALT testing by non-laboratory staff compared to conventional laboratory-based testing by professional laboratory staff; (b) point-of-care hemoglobin testing by non-laboratory staff compared to conventional laboratory-based testing by professional laboratory staff.
Fig 4Error rates for point-of-care CD4 technologies operated by non-laboratory staff.
Red forest plot and line indicate the overall pooled error rate. Blue forest plots indicate studies focused on program-wide, routine testing.